<DOC>
	<DOCNO>NCT00794482</DOCNO>
	<brief_summary>This multi-centre , multi-national , open study ass pharmacokinetics NRL972 patient hepatic cirrhosis CTP-classes A , B , C ( histologically confirm liver biopsy ) . The pharmacokinetics NRL972 reference Clinical Staging Matrix obtain clinical work-up patient hepatic cirrhosis . Patients study histologically establish hepatic cirrhosis confirm hepatic cirrhosis objective imaging study without confound end-stage co-morbidity . Within 14 day confirm eligibility , investigation conduct 2-5 day test procedure ( clinical laboratory test , ultrasound ( US ) -investigations , gastroscopy , NRL972- MEGX'-test ) . Up one week NRL972-test , follow-up telephone call make .</brief_summary>
	<brief_title>Multi-national Cirrhosis Study Characterise Association Between Pharmacokinetics NRL972 Disease Severity .</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Subjects meet follow condition eligible enrolment : Patient give write informed consent study participation , prior study specific procedure Male female ( nonchildbearing potential = postmenopausal medically adequate contraception ) Ethnicity : Age : 18 80 year age Patients histologically establish diagnosis hepatic cirrhosis available histological material review central histopathologist CTP score great equal 10 point plus objective imaging study ( CT NMR scan ) within 3 month screen visit confirmation hepatic cirrhosis ( scan collect review ) , exclude patient diagnosis primary biliary cirrhosis , primary sclerosing cholangitis cystic fibrosisassociated liver disease Present CTPclass A , B C Medically fit undergo protocoldefined procedure without undue risk discomfort Predicted lifeexpectancy great equal 6 month clinical judgement Subjects follow category exclude enrolment : Previous participation trial ( except schedule retesting relation technical difficulty initial test ) Participant trial last 90 day Donation blood last 60 day history blood loss exceed 300 mL within last 3 month Any donation germ cell , blood , organ , bone marrow course study History clinically relevant allergy ( include hypersensitivity trial medication ) Presence clinical relevant acute chronic infection ( chronic viral hepatitis , applicable ) Use confound concomitant medication Presence history endstage ( co ) morbidity ( exclude effect hepatic cirrhosis ) : malignancy clinically relevant systemic disease Suspicion evidence subject trustworthy reliable Suspicion evidence subject able make free consent understand information regard Primary biliary cirrhosis primary sclerosing cholangitis Cystic fibrosis Previous liver transplantation intend liver transplantation within 6 month enrolment Patients undergo previous transjugular intrahepatic portosystemic shunt ( TIPS ) portocaval anastomosis ( PCA ) Patients employee investigational site , relatives spouse investigator Current drug , medication abuse Special restriction female patient : Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation . Women childbearing potential , defined woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , unless meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level great 40 mIU/m 6 week post surgical bilateral oophorectomy without hysterectomy hysterectomy use one follow acceptable method contraception : surgical sterilization ( e.g. , bilateral tubal ligation , vasectomy ) , hormonal contraception ( implantable , patch , oral ) , doublebarrier method ( double combination : IUD , male female condom spermicidal gel , diaphragm , sponge , cervical cap )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>